Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Shareholder Meeting (May 2024)
13 slides from Arovella Therapeutics's shareholder meeting presentation, May 23, 2024
Slide 1: Extraordinary General Meeting May 2024
ASX:ALA For personal use only Extraordinary General Meeting May 2024
Slide 2: Arovella's strengths
Arovella’s strengths Off-the-Shelf iNKT Lead Product Addressing Key Strong For personal use only Cell Platform Advancing to Clinic Unmet Need Leadership Group Developing off-the-shelf iNKT ALA-101, potential treatment Our iNKT cell platform is Leadership team and Board cell therapies to target blood
Slide 3: Financial overview
Financial overview Financial Snapshot ASX CODE ALA ALA Price and Volume - 12 Months1 For personal use only $0.20 Market capitalisation1 $115.5 million 40,000,000 $0.18 Shares on issue 1,050.1 million $0.16 52-week low / high1 $0.042 / $0.185 $0.14 30,000,000 Cash Balance (Mar 31 2024)2 $15.31 millio
Slide 4: Introducing invariant Natural Killer T (iNKT) cells
Introducing invariant Natural Killer T (iNKT) cells Bridging the innate and adaptive immune system For personal use only Innate Immunity Adaptive Immunity ASX:ALA 4
Slide 5: iNKT cells represent a next-generation cell therapy
iNKT cells represent a next-generation cell therapy Properties make them ideal for use in cell therapy Strong safety profile For personal use only Don’t cause graft versus host disease (GvHD) Innate Front line of the human Immunity immune system Bridge innate & adaptive immune responses Contai
Slide 6: A differentiated position
A differentiated position T cell and NK cell sectors are competitive For personal use only T cell iNKT cell NK cell Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information ASX:ALA 6
Slide 7: Arovella's iNKT cell strategy
Arovella’s iNKT cell strategy Incorporating world class IP to target a range of tumour types For personal use only Foundation IP Armouring Novel CARs Regulatory Know-How Unique process to technology Unique moieties strategy Process-specific transduce iNKT cells Complementary for targeting 12-year ma
Slide 8: Exclusive worldwide rights to granted patents
Exclusive worldwide rights to granted patents Further patent claims and applications actively being pursued For personal use only Transduction and Expansion of Cells Binding Molecules Specific for Claudin 18.2 Patent life until 2038 Patent life until 2038 Method of manufacture, cell popula
Slide 9: Recent cell therapy transactions
Recent cell therapy transactions1 Upfront Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage (US$M) (US$M) value (US$M) Research May-24 T cell TBD $50 $550 $600 collaboration Dec-23 Acquisition T Cell Phase 1b $1,000 $200 $1,200 For personal use only Collaborat
Slide 10: Arovella's expanding pipeline
Arovella’s expanding pipeline For personal use only ASX:ALA 10
Slide 11: Upcoming milestones for 2024
Upcoming milestones for 2024 January July December 2024 2024 2024 For personal use only Complete cGMP manufacture for Phase 1 clinical trials Commence Phase 1 for ALA-101 targeting CD19+ ALA-101 Complete preparatory activities for Phase 1 study, lymphoma and leukemia (CD19) including preparati
Slide 12: Thank You
ASX:ALA For personal use only Thank You Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187
Slide 13: Cell therapy deal references
Cell therapy deal references 1. https://www.astellas.com/en/news/28271 2. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and- autoimmune-diseases.html For personal use only 3. https://www.astrazeneca.com/me
Arovella Therapeutics — Shareholder Meeting (May 2024) on 6ix